Suggested remit - To appraise the clinical and cost effectiveness of filgotinib within its marketing authorisation for treating moderate to severe rheumatoid arthritis
 
Status Proposed
Process STA 2018
ID number 1632

Provisional Schedule

Committee meeting 07 October 2020

Project Team

Project lead Gavin Kenny

Email enquiries

Consultees

Companies sponsors Gilead (filgotinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups National Rheumatoid Arthritis Society
Professional groups Royal College of Physicians
  Royal College of RadiologistsUK Clinical Pharmacy Association

Commentators

Comparator companies Abbvie (adalimumab)
  Accord Healthcare (methotrexate) (confidentiality agreement not signed, not participating)
  Advanz Pharma (methotrexate) (confidentiality agreement not signed, not participating)
  Amgen (adalimumab biosimilar)
  Aspire Pharma (leflunomide) (confidentiality agreement not signed, not participating)
  Biogen (adalimumab biosimilar, etanercept biosimilar, infliximab biosimilar)
  Bristol Laboratories (hydroxychloroquine) (confidentiality agreement not signed, not participating)
  Bristol-Myers Squibb (abatacept) (confidentiality agreement not signed, not participating)
  Cipla (methotrexate) (confidentiality agreement not signed, not participating)
  Eli Lilly (baricitinib)
  Hospira (methotrexate) (confidentiality agreement not signed, not participating)
  medac (leflunomide, methotrexate) (confidentiality agreement not signed, not participating)
  Merck Sharp & Dohme (golimumab, infliximab) (confidentiality agreement not signed, not participating)
  Mylan (adalimumab biosimilar, leflunomide) (confidentiality agreement not signed, not participating)
  Napp (rituximab biosimilar, infliximab biosimilar) (confidentiality agreement not signed, not participating)
  Nordic Pharma (methotrexate) (confidentiality agreement not signed, not participating)
  Orion Pharma (methotrexate) (confidentiality agreement not signed, not participating)
  Pfizer (infliximab biosimilar, tofacitinib, etanercept, methotrexate, sulfasalazine) (confidentiality agreement not signed, not participating)
  Roche (tocilizumab, rituximab) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (methotrexate, sulfasalazine) (confidentiality agreement not signed, not participating)
  Sandoz (adalimumab biosimilar, rituximab biosimilar, etanercept biosimilar, infliximab biosimilar methotrexate, leflunomide) (confidentiality agreement not signed, not participating)
  Sanofi (hydroxychloroquine, leflunomide, sarilumab) (confidentiality agreement not signed, not participating)
  Therakind (methotrexate) (confidentiality agreement not signed, not participating)
  UCB Pharma (certolizumab pegol)
  Zentiva (hydroxychloroquine, leflunomide) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
03 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
06 February 2020 Invitation to participate
01 October 2019 - 29 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance